Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „receiving“
Suchtreffer
Begriffe & Kennungen
Alymsys · 4.8 · The incidence of CNS bleeding in patients with untreated CNS metastases receiving bevacizumab has not been pro
Eintrag öffnenAlymsys · 4.8 · The most frequently observed adverse reactions across clinical trials in patients receiving bevacizumab were h
Eintrag öffnenAmbirix · 4.5 · It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, a
Eintrag öffnenApixaban Accord · 4.5 · Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatme
Eintrag öffnenApixaban Accord · 4.5 · The use of apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibi
Eintrag öffnenApixaban Accord · 4.5 · The use of apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibi
Eintrag öffnenAqumeldi · 4.5 · Patients receiving concomitant ACE inhibitor and neprilysin inhibitor therapy (e.g., sacubitril, racecadotril)
Eintrag öffnenAqumeldi · 4.8 · The adverse reaction frequency listed in Table 1 is derived from the clinical studies in children receiving AQ
Eintrag öffnenAranesp · 4.8 · Convulsions have been reported in patients receiving darbepoetin alfa (see section 4.4). The frequency is esti
Eintrag öffnenAranesp · 4.8 · Convulsions have been reported in patients receiving darbepoetin alfa in post-marketing experience (see sectio
Eintrag öffnenArava · 4.5 · If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, thes
Eintrag öffnenArava · 4.5 · If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, thes
Eintrag öffnenArava · 4.5 · If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, thes
Eintrag öffnenArava · 4.5 · It is recommended that patients receiving leflunomide are not treated with colestyramine or activated powdered
Eintrag öffnenArava · 4.5 · It is recommended that patients receiving leflunomide are not treated with colestyramine or activated powdered
Eintrag öffnenArava · 4.5 · It is recommended that patients receiving leflunomide are not treated with colestyramine or activated powdered
Eintrag öffnenAripiprazole Sandoz · 4.8 · 12 that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripipraz
Eintrag öffnenArsenic trioxide Accord · 4.8 · 10 or hypomagnesaemia. One patient (receiving multiple, concomitant medicinal products, including amphotericin
Eintrag öffnenAtazanavir Viatris (previously Atazanavir Mylan) · 4.8 · Laboratory abnormalities The most frequently reported laboratory abnormality in patients receiving regimens co
Eintrag öffnenAtazanavir Viatris (previously Atazanavir Mylan) · 4.8 · Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in ≥ 2% of patients receiving regimens
Eintrag öffnen